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ABSTRACT 
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D- 
Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in 
humans in vivo and in animals in vitro and in vivo via a still unknown 
receptor and mechanism. To determine the effect of GHRP on human 
somatotroph cells in vitro, we stimulated cell cultures derived from 12 
different human somatotroph adenomas with GHRP alone and in 
combination with GH-releasing hormone (GHRH), TRH, and the 
somatostatin analog octreotide. GH secretion of all 12 adenoma cultures 
could be stimulated with GHRP, whereas GHRH was active only in 6 
adenoma cultures. In GHRH-responsive cell cultures, simultaneous 
application of GHRH and GHRP had an additive effect on GH secre- 
tion. TRH stimulated GH release in 4 of 7 adenoma cultures: in TRH- 
responsive cell cultures there was also an additive effect of GHRP and 
TRH on GH secretion. In 5 of 9 adenoma cultures investigated, 
octreotide inhibited basal GH secretion. In these cell cultures, GHRP- 
induced GH release was suppressed by octreotide. In 5 of 5 cases, the 
nrotein kinase-C inhibitor uhloretin nartlv inhibited GHRP-stimulated 
bH release, but not basal GH secretion. In summary, GH secretion 
was stimulated by GHRP in all somatotroph adenomas investigated, 
indicating that its unknown receptor and signaling pathway are ex- 
pressed more consistently in somatotroph adenoma cells than those for 
GHRH, TRH, and somatostatin. Our data give further evidence that 
GHRP-stimulated GH secretion is mediated by a receptor different 
from that for GHRH or TRH, respectively, and that protein kinase-C 
is involved in the signal transduction pathway. Because human soma- 
totroph adenoma cell cultures respond differently to various neuropep- 
tides (GHRH, TRH, somatostatin, and others), they provide a model 
for further investigation of the mechanism of action of GHRP-induced 
GH secretion. (J Clin Endocrinol Metub 78: 1090-1096, 1994) 
G H-RELEASING peptide (GHRP), a synthetic hexapep- tide (His-n-Trp-Ala-Trp-o-Phe-Lys-NH*) derived 
from enkephalins (1, 2), specifically stimulates GH secretion 
of somatotroph pituitary cells in animals both in uivo and in 
vitro (3, 4) as well as in normal humans (5-7), short-statured 
children (8), and patients with acromegaly (9) in viva. Because 
in humans GHRP is approximately as active as GH-releasing 
hormone (GHRH) and, moreover, can be administered orally, 
it may provide an alternate form of treatment of certain 
forms of GH deficiency (5-7, 10). 
Previous studies demonstrated that GHRP does not stim- 
ulate GH release via the GHRH receptor (11, 12), the opiate 
receptors (13), or the receptor for pituitary adenylate cyclase- 
activating polypeptide (14). Although the receptor for GHRP 
is not known, and the mechanism by which GHRP stimulates 
GH release is not well understood (15), part of the action of 
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GHRP seems to be mediated via protein kinase-C (PKC) (16). 
In this case, the action of GHRP is similar to that of phorbol 
12-myristate 13-acetate. Previous studies investigating the 
interaction of GHRP with GHRH and somatostatin (SRIF) 
have demonstrated that SRIF suppresses GHRP-stimulated 
GH release (3, 11, 15), and GHRP and GHRH stimulate GH 
secretion in a synergistic fashion (5, 15, 16). GHRP-binding 
sites were detected not only in pituitary, but also in hy- 
pothalamic membrane fractions (17). Therefore, besides its 
action at the pituitary level, the possibility of a hypothalamic 
site of action of GHRP is still under discussion. 
Somatotroph pituitary adenomas represent approximately 
20% of the pituitary adenomas and cause acromegaly or 
gigantism due to GH hypersecretion under basal conditions 
(18). In normal somatotrophs, GH secretion is under control 
of the stimulatory action of hypothalamic GHRH and the 
inhibitory effect of its counterpart, SRIF (19). The disturb- 
ances in GH secretion of somatotroph adenoma cells, in 
addition to the quantitative abnormality of basal secretion, 
may involve qualitative abnormalities in the regulation of 
GH secretion, such as lack of stimulation by GHRH, para- 
doxical increase in GH after stimulation with TRH (18), and 
missing inhibition after administration of SRIF or SRIF ana- 
logs such as octreotide in a part of the adenomas (20, 21). 
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The lack of GH stimulation by GHRH can be observed in 
about 30-40% of the somatotroph adenomas and was found 
to be due to the expression of the gsp oncogene (22). This 
oncogene is derived from a single mutation in the a-chain of 
the regulatory guanosine stimulatory G-protein (G,) and 
leads to a constitutive activation of the adenylate cyclase 
system (23). As a result, CAMP production and associated 
GH secretion cannot be further stimulated by GHRH; there- 
fore, GH secretion of this tumor type fails to respond to 
GHRH stimulation (24, 25). 
The aim of the present study was to determine whether 
somatotroph adenomas in vitro respond differently to GHRP 
with respect to GH secretion, as has been found for GHRH, 
TRH, and somatostatin. In addition, with somatotropic cell 
cultures, the effect of GHRP on GH release was studied 
comparatively with GHRH, TRH, and octreotide. 
Materials and Methods 
Patients 
Pituitary adenoma tissue from 12 patients with somatotroph tumors 
(numbered consecutively ST 1 to ST 12) obtained at transsphenoidal 
surgery was studied. The presence of pituitary adenomas was confirmed 
by computerized tomography or magnetic resonance imaging. ST 2 was 
a recurrent adenoma from a patient who had undergone a first surgery 
14 yr previously. ST 4 was from a patient treated with octreotide (three 
doses; 100 fig daily) over a period of 4 months before surgery. The 
clinical data of the patients are shown in Table 1. 
Cell culture 
Cell culture materials and reagents, except where stated, were ob- 
tained from Flow Laboratories (Meckenheim, Germany), Gibco Europe 
(Karlsruhe, Germany), Seromed (Berlin, Germany), Falcon (Heidelberg, 
Germany), or Nunc (Wiesbaden, Germany). 
Human pituitary adenoma cell cultures were performed as described 
previously (26) with minor modifications. In brief, adenoma tissue was 
washed four times with preparation buffer [137 mmol/L NaCl, 5 mmol/ 
L KCl, 0.7 mmol/L NazHP04, 15 mmol/L HEPES (pH 7.3), 10 mmol/L 
glucose, 2.5 mg/L amphotericin-B, and 10’ U/L penicillin/streptomycin] 
and dissected into small pieces. The tissue fragments were mechanically 
and enzymatically dispersed in preparation buffer containing 1000 U/ 
mL collagenase (Worthington Biochemical Corp., Freehold, NJ), 4 g/L 
BSA, 10 mg/L DNAase-II, 1 g/L soybean trypsin inhibitor, and 2 g/L 
hyaluronidase. Dispersed cells were centrifuged and resuspended in 
sterile culture medium (Dulbecco’s Modified Eagle’s Medium, pH 7.3) 
containing 10% fetal calf serum (FCS), 2.2 g/L NaHC03, 10 mmol/L 
HEPES, 2 mmol/L glutamine, 10 mL/L nonessential amino acids, 10 
mL/L Minimum Essential Vitamins, 5 mg/L insulin, 5 mg/L transferrin, 
2.5 mg/L amphotericin-B, lo5 U/L penicillin/streptomycin, 20 pg/mL 
sodium Selenit (Sigma Chemical Co., St. Louis, MO), and 30 pmol/L T3 
(Henning, Berlin, Germany). Between 22-40 X lo6 cells with a viability 
of 92-98% (acridine orange-ethidium bromide staining) were isolated 
from pituitary tumors. The cells were diluted with culture medium and 
distributed to 24.well tissue culture plates (2 X lo5 cells/well in 1 mL 
medium). The cells were grown at 37 C in an atmosphere of 5% CO,. 
The dispersed cells attached to the culture dishes within the first 48 h. 
Incubation of the cells with test substances 
Experiments were conducted on cells 2-3 days after plating. The 
growth medium was removed by aspiration, and the attached cells were 
washed several times with phosphate-buffered saline. For stimulation 
experiments, Dulbecco’s Modified Eagle’s Medium (pH 7.3) supple- 
mented with 2.2 g/L NaHC03, 10 mmol/L HEPES, 2 mmol/L glutamine, 
1 g/L BSA, and 30 mg/L ascorbic acid (as an antioxidant) was used. 
GHRI’ (SmithKline Beecham, King of Prussia, PA), GHRH and TRH 
(both from Bachem, Bubendorf, Switzerland), the somatostatin analog 
octreotide (SMS 201-995; Sandoz, Basel, Switzerland), and the I’KC 
inhibitor phloretin (Sigma Chemical Co., St. Louis, MO) (16, 27) were 
diluted in the same medium and added in the concentrations indicated. 
For studies in which combinations of the test substances were used, 
GHRP and GHRH were added to give concentrations of 1, 10, and 100 
nmol/L of each; GHRP and TRH or octreotide, respectively, were applied 
in concentrations of 10 or 100 nmol/L of each. The final volume was 1 
mL/well in each case. After an incubation period of 4 h, which was 
determined to be the optimal incubation time for all of the various test 
substances, the supernatants were removed and assayed for GH. Due 
to the limited numbers of cells obtained at some tumor cell preparations, 
not all studies could be performed in parallel with every somatotroph 
adenoma. 
Determination of human (h) GH, PRL, and insulin-like growth 
factor-I 
hGH levels in cell culture supernatants were determined using a 
sensitive fluorescence immunometric assay, as described previously (28) 
TABLE 1. Clinical characteristics of the 12 patients with somatotroph adenomas (ST 1 to ST 12) 
Preoperative serum GH (pg/L) 
Tumor Age 
no. (yd 
Sex 
Duration of 
illness (yr) 
Adenoma 
extension Basal 
After TRH 
(200 a, 
iv) 
After OGTT 
(100 g 
glucose) 
IGF-I PRL Pituitary 
After GHRH bG/L) b&!/L) function 
(100 rrg, iv) 
ST 1 58 F 4 Intra/suprasellar 59 113 123 NE 1507 13.7 Normal 
ST2 54 M >16 Intra/parasellar 91 123 98 114 1080 15.1 Normal 
ST3 60 F 5 Intrasellar 13 28 17 NE 1264 16.2 SH 
ST4 55 F 3 Intra/parasellar 89 134 109 NE 561 41.8 Normal 
ST5 66 F 3 Intrasellar 12 15 20 NE 1340 4.8 Normal 
ST6 66 F 10 Intra/parasellar 10 27 15 NE 1495 11.9 Normal 
ST7 28 F 5 Parasellar 13 14 8 17 964 6.0 SH 
ST8 34 F >lO Intrasellar 15 48 13 NE 1343 11.3 Normal 
ST9 27 F 4 Intra/parasellar 83 110 58 147 1146 7.2 SH 
ST 10 55 M 1 Intrasellar 36 94 31 137 2259 28.6 Normal 
ST11 41 F” 5 Intra/suprasellar 37 62 33 56 2137 12.3 Normal 
ST 12 59 5 Intra/parasellar 46 53 41 NE 972 10.9 Normal 
Clinical characteristics of the patients from which the somatotroph adenomas were obtained. GH (normal, <5 pg/L) was determined with a 
fluorescence immunoassay, as described in Materials and Methods. IGF-I (normal range in adults, 180-480 pg/L) was determined using a kit from 
Nichols, and PRL (normal, 1-25 pg/L) was determined with a DELFIA kit. F, Female; M, male; NE, nonevaluable; OGTT, oral glucose tolerance 
test; SH, secondary hypogonadism. 
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with minor modifications. In brief, anti-hGH monoclonal antibody clone 
8811 was adsorbed to polystyrene microtiter plates (500 ng antibody/ 
well) in 50 mmol/L phosphate buffer, pH 9.6. After 16-h incubation at 
4 C, the plates were washed, and 50 @L sample (diluted I:20 to 1:50) or 
standard were added. Standards were prepared by serial dilution of 
recombinant hGH (Genotropin, Kabi, Stockholm, Sweden). Then, 30 ng 
biotinylated anti-hGH monoclonal antibody clone 7F8 in 150 PL assay 
buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.5% BSA, 0.05% (wt/ 
vol) bovine y-globulin, 0.05% Tween-40, 0.05% NaNa, and 20 pmol/L 
diethylenetriaminepentaacetic acid, pH 7.751 were added. After 2 h of 
incubation at room temperature, the plates were washed again, and 10 
ng streptavidin-europium conjugate (Kabi-Pharmacia, Freiburg, Ger- 
many), dissolved in assay buffer, were added to each well (final volume, 
200 pL). After an incubation period of 30 min at room temperature and 
a final wash step, 200 PL europium fluorescence enhancement solution 
(Kabi-Pharmacia) were added, and the europium signal was measured 
in a time-resolved fluorometer (DELFIA, Wallacoy, Turku, Finland). The 
working range for cell culture samples was 0.12-100 ng/mL, with an 
intraassay coefficient of variation of less than 10%. 
Serum GH levels were measured with the same method, using 
commercially available hGH standards prepared in ovine serum (Med- 
genix, Ratingen, Germany). The working range for serum samples is 
0.18-110 ng/mL. 
Insulin-like growth factor-I serum levels were determined with a RIA 
kit (Nichols Institute, Bad Nauheim, Germany) after acid-ethanol ex- 
traction and cryoprecipitation. Serum PRL was measured with a DELFIA 
kit (Wallacoy). Both methods were conducted according to the instruc- 
tions of the manufacturers. 
Statistics 
All experiments were performed at least in quadruplicate, and values 
are calculated as the mean + SD and, with the exception of the data 
presented in Table 2, are expressed as a percentage of the control values. 
Statistics were determined by analysis of variance in combination with 
the Scheffe test. P < 0.05 was considered significant. 
Results 
Basal and stimulated GH secretion 
In vitro basal GH secretion varied from 107 (ST 2) to 438 
(ST 12) ng GH/2 X lo5 cells. 4 h (Table 2). There was no 
correlation between basal GH secretion in vitro and plasma 
GH levels in uivo (compare with Table 1). As far as compa- 
rable, the responsiveness to GHRH and TRH was identical 
in viva and in vitro, with the exception of ST 11, in which 
GHRH stimulated GH release in viva but not in vitro (com- 
pare Tables 1 and 2). 
GHRP (0.1-1000 nmol/L) stimulated GH release in a dose- 
dependent manner in all 12 somatotroph adenoma cell cul- 
tures (a typical dose-response curve is shown in Fig. 1; see 
also Table 2 and Fig. 2). In all cases the stimulatory effects 
became significant at 1 nmol/L (range, 120 + 2% to 148 f 
9% US. basal secretion) and reached a plateau at 10 nmol/L 
(range, 126 f 4% to 184 + 12%); no further significant 
stimulation of GH secretion could be observed with either 
100 or 1000 nmol/L GHRP (range, 123 f 4% to 202 + 8%). 
GHRH (0.1-1000 nmol/L) stimulated GH secretion in six 
adenoma cell cultures dose dependently, but had no signifi- 
cant stimulatory effect in the six other cultures (for typical 
dose-response curve of a GHRH-responsive culture, see Fig. 
1; see also Table 2 and Fig. 2). For GHRH-responsive cultures, 
stimulatory effects became significant at 1 nmol/L (127 f 
1% and 134 + 4%) in two cases (ST 1 and ST lo), and at 10 
TABLE 2. In vitro characteristics of the somatotroph adenoma cell 
cultures 
Tumor Basal GH 
IIO. secretion 
Responsive in uitro to 
GHRP GHRH TRH Octreotide 
ST 1 293 
ST2 107 
ST3 241 
ST4 176 
ST5 195 
ST6 392 
ST7 117 
ST8 208 
ST9 156 
ST 10 354 
ST 11 144 
ST 12 438 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ ND ND 
- ND ND 
- ND -= 
- ND ND 
- ND - 
+ + + 
- - + 
+ + -a 
+ - + 
+ + - 
- + + 
+ - + 
Characteristics of the 12 somatotroph adenoma cell cultures inves- 
tigated with respect to basal GH secretion (nanograms of GH per 2 x 
lo5 cells/4 h) and responsiveness to stimulation with GHRP, GHRH, 
TRH, and octreotide. Cell cultures that responded to 1 or 10 nmol/L 
of the substances with a significant increase or decrease in GH secretion 
(P < 0.05) were considered to be responsive (+). Cell cultures in which 
GH secretion could not be stimulated by excessively high concentra- 
tions (100 or 1000 nmol/L) of the test substances were considered not 
responsive (-). ND, Not determined. 
’ Significant (P < 0.05 us. control) inhibition of GH secretion only 
at 1000, but not at 100 nmol/L octreotide. 
-995 
40.4” 
0 O,l 1 10 100 1000 
Concentration (nmol/L) 
FIG. 1. Influence of increasing concentrations of GHRP, GHRH, 
TRH, and octreotide (SMS 201-995) on GH secretion of cultured cells 
of the somatotroph adenoma ST 6. In vitro, this adenoma responded 
to all of the substances tested, and significant stimulation of GH 
secretion could be observed after treatment with GHRP, GHRH, and 
TRH as well as significant inhibition of GH secretion after application 
of octreotide. t, P < 0.05; tt, P < 0.01 [U.S. basal GH secretion (lOO%)]. 
nmol/L (range, 124 + 3% to 135 + 7%) in four cases (ST 6, 
8, 9, and 12). Maximal stimulation was obtained with 100 
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GH+FIH (100 nmol/L) 
a 
GHRP GHRP (100 nmol/L) 
+ 
a tt 
r Ii 
(100 nmol/L) / 4: /4 
ST1 ST6 ST8 ST9 ST10 ST12 ST2 ST3 ST4 ST5 ST7 ST11 
GHRH “responder” GHRH “nonresponder” 
FIG. 2. Comparison of the effects of GHRH (100 nmol/L) and GHRP (100 nmol/L), either alone or in combination, on the GH secretion of 12 
individual adenoma cell cultures (ST 1 to ST 12). Basal secretion of the adenoma cultures was set at lOO%, and the results of the stimulation 
experiments are expressed as a percentage of the control value. *, P < 0,05; tt, P < 0,Ol (us. control). In GHRH responders, simultaneous 
application of GHRH and GHRP led to a further significant increase in GH secretion (a, P < 0.05; b, P < 0.01) compared to stimulation with 
GHRP alone. 
nmol/L (range, 136 + 4% to 158 + 9%). No further significant 
increase could be observed with 1000 nmol/L GHRH (range, 
130 + 7% to 163 AZ 7%). 
The effect of TRH (0.1-1000 nmol/L) on GH secretion 
was tested in seven somatotroph adenoma cell cultures. In 
three of them, TRH had no significant effect, but stimulated 
GH release dose dependently in the other four cultures (Fig. 
1; see also Table 2 and Fig. 3). In the TRH responders the 
stimulatory effect became significant at 10 nmol/L (range, 
129 f 5% to 159 + 9% us. basal secretion) and reached 
maximum values at 100 nmol/L (range, 138 + 7% to 174 + 
4%), with the exception of one case (ST 8) in which a further 
significant stimulatory effect of TRH was observed with 1000 
nmol/L (161 f 8% VS. 138 rf: 7% at 100 nmol/L). 
Although the use of lo-fold increments was critical, we 
calculated the approximate EDs0 values for GHRP, GHRH, 
and TRH for the individual somatotroph adenomas to obtain 
information about the relative GH-stimulating potency of 
these substances. The EDso for GHRP ranged from 1.1-3.4 
nmol/L, the ED50 for GHRH (in GHRH responders) from 
FIG. 3. Comparison of the effects of 
TRH (100 nmol/L) and GHRP (100 
nmol/L), either alone or in combination, 
on the GH secretion of seven individual 
somatotroph adenoma cell cultures (ST 
6 to ST 12). Results are expressed as a 
percentage of the control value (100% = 
basal secretion). *, P < 0.05; **, P < 
0.01 (US. control). In TRH responders, 
simultaneous application of TRH and 
GHRP significantly stimulated GH se- 
cretion (a, P < 0.05; b, P < 0.01) com- 
pared to stimulation with GHRP alone. 
ST6 ST8 ST10 ST11 ST7 ST9 ST12 
TRH “responder” TRH “nonresponder” 
1094 RENNER ET AL. JCE & M ~1994 
Vol%.No5 
2.9-9.1 nmol/L, and the EDso for TRH (in TRH responders) 
from 6.4-12.5 nmol/L. 
The influence of octreotide (0.1-1000 nmol/L) on basal 
GH release was studied with nine somatotroph adenoma cell 
cultures (Fig. 1; see also Table 2 and Fig. 4). Four adenoma 
cultures (ST 3, 5, 8, and 10) were considered to be not or 
only slightly responsive to octreotide, because l-100 nmol/ 
L octreotide had no significant inhibitory effect on GH secre- 
tion. In only two cases (ST 3 and ST 8) was a slight, but 
significant, inhibition (P < 0,05) of basal GH release observed 
after application of 1000 nmol/L octreotide (79 + 4% and 83 
f 1% of basal secretion). In contrast, five adenomas re- 
sponded very well to octreotide. In one of these (ST 6), basal 
GH secretion was significantly inhibited by 1 nmol/L octreo- 
tide (80 k 2%); GH was stimulated in all cases by 10 nmol/ 
L (range, 69 f 6% to 81 f 3%). Basal GH release was further 
decreased by 100 nmol/L octreotide (range, 51 f 9% to 70 
+ 4%), but 1000 nmol/L had no further significant inhibitory 
effect (range, 48 + 4% to 65 f 8%). 
Interaction of GHRH and GHRP on GH secretion 
In all somatotroph adenoma cultures the effects of GHRP 
and GHRH were investigated simultaneously (Fig. 2 sum- 
marizes the results for the stimulation with 100 nmol/L of 
each compound). In the six adenomas in which GH secretion 
could not be stimulated with GHRH, simultaneous applica- 
tion of GHRP and GHRH had the same stimulatory effect as 
GHRP alone. In the GHRH-responsive cell cultures, simul- 
taneous stimulation with 100 nmol/L GHRP and GHRH had 
an additive effect on GH release (GHRP plus GHRH, 186 + 
3% to 225 + 7%; GHRP alone, 146 f 2% to 181 + 10% US. 
basal secretion). This additive effect was also observed when 
combinations of the substances were used at lower concen- 
trations (1 and 10 nmol/L; data not shown). 
Interaction of TRH and GHRP on GH secretion 
In 7 of 12 adenoma cell cultures we studied the effects of 
GHRP and TRH on the GH release (Fig. 3 summarizes the 
FIG. 4. Effect of 100 nmol/L octreotide 
(SMS 201-995) on basal and GHRP (100 
nmol/L)-stimulated GH secretion of 
nine individual somatotroph adenoma 
cell cultures (ST 3 and ST 5 to ST 12). 
Basal GH secretion was set at lOO%, and 
results are expressed as a percentage of 
the control value. t, P < 0.05; **, P < 
0.01 (us. control). In cell cultures in 
which basal GH secretion could be sig- 
nificantly suppressed by octreotide, 
GHRP-stimulated GH secretion was 
also inhibited significantly (a, P < 0.01; 
b, P < 0.001). 
n 
USMS 201-995 (100 nmOl/L) 
effects for 100 pmol/L of each substance). In the 3 TRH 
nonresponders, simultaneous application of GHRP and TRH 
resulted in the same stimulatory effect as application of 
GHRP alone. In TRH-responding somatotroph adenoma cul- 
tures, simultaneous application of 100 nmol/L GHRP and 
TRH had an additive effect on GH secretion (GHRP plus 
TRH, 181 f 2% to 239 + 9%; GHRP alone, 154 + 9% to 184 
+ 12% US. basal secretion). The additive effect could also be 
seen, but was less pronounced, when 10 nmol/L TRH or 
GHRP were used (data not shown). 
Effect of octreotide on GHRP-stimulated GH secretion 
In 9 of 12 somatotroph adenoma cell cultures, the effect 
of the long-acting somatostatin analog octreotide (10 and 
100 nmol/L) on GHRP-stimulated GH release was investi- 
gated. In Fig. 4, the effects of 100 nmol/L octreotide on basal 
and GHRP-stimulated GH secretion are summarized (the 
effects of 10 nmol/L octreotide were similar, but less pro- 
nounced). In the 4 adenoma cell cultures that failed to 
respond or showed only a moderate response to octreotide, 
GHRP-induced GH secretion could not be significantly sup- 
pressed. In the adenoma cultures that responded to octreo- 
tide, however, significant decreases in GHRP-stimulated GH 
secretion could be observed after application of 100 nmol/L 
octreotide (GHRP alone, 136 + 3% to 184 + 12%; GHRP 
plus octreotide, 75 + 8% to 106 + 4% vs. basal secretion). 
Influence of phloretin on GHRP-stimulated GH release 
In 5 of 12 cases (ST 8 to ST 12), the effects of phloretin 
(10 and 100 pmol/L), an inhibitor of PKC, on basal and 
GHRP-stimulated GH release were investigated (Table 3). 
Phloretin had no cytotoxic effect on the cells, as demon- 
strated by viability staining using ethidium bromide and 
a&dine orange. In all cases, even the high concentration of 
phloretin had no significant inhibitory effect on basal GH 
secretion (range, 91 + 8% to 98 f 6% vs. basal secretion). 
GHRP-stimulated GH secretion was significantly inhibited 
GHRP (100 nmol/L) SMS 201-995 + GHAP (100 nmol/L of each) 
225 b 
1 1 200 ‘1 
a 175 
b 
z 150 
‘tj 
e 125 
5 
‘k= 
2 100 
P 
3 75 
50 
25 
- 
ST6 ST7 ST9 ST11 ST12 ST3 I I 
ST5 ST6 ST 10 
I I I 
SMS 201-995 “responder” SMS 201-995 “nonresponder” 
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TABLE 3. Effect of phloretin on GHRP-stimulated GH secretion 
1095 
Tumor no. ST8 ST9 ST 10 ST 11 ST 12 
Basal 100 f 7 100 e 4 100 + 5 100 k 5 100 + 7 
10 rmol/L phloretin 94 + 3 96 f 5 100 f  3 102 c 3 94 + 5 
100 Fmol/L phloretin 92 + 6 96 -t 1 97 f 3 98 + 6 91 + 8 
100 nmol/L GHRP 154 + 9 146 f  2 163 f  6 160 + 5 181 f  10 
GHRP + 10 pmol/L phloretin 143 + 6 137 + 7 138 -t 1” 133 + 4” 169 + 10 
GHRP + 100 +mol/L phloretin 128 + 7’ 121 f 4” 129 k 4” 119 +- 1’ 145 k 1” 
The effect of the PK-C inhibitor phloretin was investigated on both basal and GHRP (100 nmol/L)-stimulated GH secretion of five individual 
somatotroph adenoma cell cultures. Each value represents the mean & SD of quadruplicate determinations and is expressed as a percentage of the 
control value (basal secretion). Significance was determined US. GH stimulation with 100 nmol/L GHRP. 
“P < 0.01. 
* P < 0.05. 
c P < 0.001. 
by 10 pmol/L phloretin in 2 of 5 cases and in all cases by 
lb0 pmol/L phloretin. With the latter concentration, the 
maximum stimulatory effect of GHRP was reduced by 50- 
60%. 
Discussion 
The abnormal regulation of GH secretion in somatotroph 
adenoma cells involves basal GH hypersecretion and, in 
some of the adenomas, missing response to GHRH, paradox- 
ical response to TRH, and missing inhibition response to 
somatostatin or its analogs (18-21). Here we report that in 
vitro, GHRP stimulated GH secretion in all 12 somatotroph 
adenoma cell cultures investigated, whereas GHRH stimu- 
lated GH release in only 6 of 12 cases and TRH increased 
GH secretion in 4 of 7 cases. Our data confirm the results of 
a recent in vim study in which it was shown that GHRP 
stimulated GH secretion in all 11 patients with acromegaly 
investigated (9). Our observation that GHRP was active in 
GHRH and TRH nonresponders confirms previous studies 
that GHRP acts through a receptor and a mechanism on GH 
secretion distinct from those of GHRH and TRH. This was 
further supported by our observation that the combined 
stimulation with GHRP and either GHRH or TRH had an 
additive effect on GH secretion, even in concentrations at 
which each of the substances alone had its maximal effect 
(5-7, 11). 
Comparing the EDso values of GHRP and GHRH for 
GHRH-responsive somatotroph adenoma cultures, GHRP is 
even more potent than GHRH in stimulating GH secretion. 
This is in agreement with in vim findings, where it has been 
demonstrated that in most patients with acromegaly GHRP 
was more effective than GHRH in stimulating GH release 
(9). Previous studies have also shown that, in general, GHRP 
is nearly as potent as GHRH in stimulating GH secretion in 
humans, whereas GHRP is about lOO-fold less active than 
GHRH in rats (3-5). There is still no explanation for this 
phenomenon; human somatotroph adenoma cell cultures 
could provide a model for further studies on this topic. 
In GHRH nonresponders, the missing effect of GHRH on 
GH secretion has been correlated with the expression of the 
gsp oncogene (22, 23). The expression of this oncogene leads 
to a constitutive activation of the adenylate cyclase system, 
and because GHRH mediates GH secretion via this second 
messenger system, the GH secretion is not or is only poorly 
stimulated by GHRH (24, 25). However, because the corre- 
lation between gsp expression and GHRH nonresponsiveness 
is not lOO%, and exceptions were found (24, 25), we cannot 
be sure that all of our GHRH nonresponders are gsp positive. 
On the other hand, because about 40% of the somatotroph 
adenomas express the gsp oncogene, by extrapolation, it 
would seem that GHRP is able to stimulate GH secretion in 
both gsp-negative and gsp-positive adenoma cells. 
The mechanism of the paradoxical response of GH secre- 
tion to TRH stimulation observed in some somatotroph ad- 
enomas is not yet completely understood, but there is evi- 
dence that the TRH receptor is expressed in TRH responders, 
and the phosphoinositol pathway and PKC may be involved 
(29, 30). It is known from studies in rats that GHRP-stimu- 
lated GH secretion is also in part mediated via PKC (16). We 
could confirm this by the observation that in five somato- 
troph adenoma cultures investigated, the PKC inhibitor 
phloretin inhibited GHRP-stimulated GH secretion. On the 
other hand, we could show that GHRP and TRH in TRH- 
responsive adenoma cultures exerted an additive effect on 
GH secretion even at maximal stimulatory concentrations of 
each alone. Therefore, although the stimulation of GH by 
GHRP and TRH may share a common intermediate sub- 
stance, namely PKC, the availability of PKC does not seem 
to be the rate-limiting step in the combined action of TRH 
and GHRP on GH secretion. 
GH hypersecretion in acromegaly can often be reduced by 
medical treatment with somatostatin analogs, like the long- 
acting analog octreotide. On the other hand, in some cases 
GH secretion is not influenced by octreotide (18, 19, 21). The 
different responses of the somatotroph adenomas to so- 
matostatin analogs have recently been recognized to be as- 
sociated with the different expression of various somatostatin 
receptor subtypes that differ in their affinity to somatostatin 
or somatostatin analogs (21). Thus, tumors that do not re- 
spond to octreotide do not express the appropriate receptor. 
In our study, basal GH secretion of five of nine somatotroph 
adenoma cell cultures could be inhibited by octreotide. In 
these responders, GHRP-stimulated GH secretion was also 
suppressed significantly by octreotide. In contrast, octreotide 
had no inhibitory effect on GHRP-induced GH release in 
1096 RENNER ET AT. JCE & M. 1994 __I. 
those adenoma cultures in which it was not able to suppress 
basal GH secretion. Therefore, independent from its mech- 
anism, GHRP-stimulated GH secretion seems to be under 
the control of somatostatin, as was also shown in rats (3, 11, 
15), and can be inhibited in somatotroph adenoma cells that 
respond to octreotide. 
In summary, GHRP was able to stimulate GH secretion 
dose dependently in all 12 human somatotroph adenoma 
cell cultures investigated. Thus, the expression of both the 
still unidentified receptor of GHRP and its unknown signal- 
ing pathway seems to be more consistent in somatotroph 
adenomas than in those for GHRH, TRH, and somatostatin, 
in which marked variations in different somatotroph ade- 
noma subtypes with respect to stimulation or inhibition of 
GH secretion are observed. The action of GHRP is different 
from that of GHRH and TRH, but can be blocked by octreo- 
tide in octreotide-responsive adenomas. Although we could 
confirm the participation of PKC in GHRP-stimulated GH 
secretion, much more work is necessary to identify the mech- 
anism of action of GHRP and to characterize its receptor. 
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